ANI Pharmaceuticals, Inc. (ANIP)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Generics and Other	399.43M	320.03M	289.31M	235.24M	-
Rare Disease and Brands	483.93M	294.34M	197.50M	81.15M	-
Generics, Established Brands, and Other	-	-	-	-	216.14M
Total	883.37M	614.38M	486.82M	316.39M	216.14M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	852.44M	604.99M	486.25M	312.43M	211.89M
International	30.92M	9.39M	565.00K	3.96M	-
Canada	-	-	-	-	4.24M
Total	883.37M	614.38M	486.82M	316.39M	216.14M

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 7, 2026

Data Sources Report a data error